REMS Program

Because of the risk of hepatotoxicity, Juxtapid is available only through a restricted program called the JUXTAPID REMS Program. Aegerion Pharmaceuticals has worked with the US Food & Drug Administration (FDA) to develop this Risk Evaluation and Mitigation Strategy (REMS) Program to:

Educate prescribers about:

  • the risk of hepatotoxicity associated with the use of Juxtapid; and
  • the need to monitor patients during treatment with Juxtapid as per product labeling.

Restrict access to therapy with Juxtapid to patients with a clinical or laboratory diagnosis consistent with HoFH.

Getting started in the Juxtapid REMS Program is straightforward.
Learn more at the Juxtapid REMS Program website, or by email.

Phone: 1-855-898-2743
 Monday-Friday: 8 AM-7 PM ET
Fax: 1-855-898-2498


To learn more about the risk of hepatotoxicity associated with the use of Juxtapid, please refer to the Prescribing Information.